The Wegovy pill is oral semaglutide at a 25mg maintenance dose — the first oral GLP-1 medication licensed for weight management.[1] The MHRA approved it in the UK on 11 June 2026.[2] In its main trial, people lost about 16.6% of their weight when they took it as prescribed, against 2.7% on placebo.[1] It is the same molecule as the Wegovy injection, and it must be taken on an empty stomach.
What the Wegovy pill is
Semaglutide is a GLP-1 receptor agonist: it mimics a natural gut hormone that increases fullness and reduces hunger, which drives the weight loss seen with this class of medicine.[5] UK patients already know it as the active ingredient in the Wegovy injection and in Ozempic. The "Wegovy pill" is that same molecule as a swallowed tablet at a once-daily 25mg maintenance dose — the first oral GLP-1 licensed for weight management in adults.[1]
Turning a peptide like semaglutide into a pill is hard, because peptides are broken down in the stomach. Oral semaglutide gets round this by being co-formulated with an absorption enhancer that briefly protects it.[4] That one piece of chemistry is why the tablet must be taken in a particular way (below), and why it sits in a different category from the newer small-molecule tablet orforglipron — covered on our Foundayo page — which is not a peptide and needs none of those restrictions.
Approval status: the UK's first weight-loss tablet
The Wegovy pill was first approved in the United States by the Food and Drug Administration on 22 December 2025, as the first oral GLP-1 for weight loss in adults.[1] The UK followed about six months later: the MHRA licensed it on 11 June 2026, making it the first GLP-1 tablet for weight loss authorised in the UK.[2] As of mid-2026 no EU-wide approval had been confirmed, so the UK licence came ahead of the rest of Europe.
An MHRA licence means a medicine can lawfully be prescribed in the UK. It does not mean the NHS routinely funds it — that is a separate decision by the National Institute for Health and Care Excellence (NICE), which weighs clinical and cost-effectiveness.[2] The Wegovy injection is already appraised for restricted NHS use under NICE guidance TA875; the tablet would need its own appraisal.[6]
How the Wegovy pill is dosed
The target, or maintenance, dose is 25mg once daily.[1] Nobody starts there. As with every GLP-1 medication, the dose is titrated — started low and stepped up in stages, holding each step for a minimum of about a month. UK prescribing guidance reports a ladder of 1.5mg, then 4mg, then 9mg, then 25mg once daily. This is not optional pacing: it reduces the dose-related gastrointestinal side effects that are worst as the dose climbs.[5] People already on the 2.4mg once-weekly Wegovy injection can, per that guidance, move straight across to the 25mg tablet. Either way, the pace and dose are the prescriber's call.
Because the tablet relies on that brief absorption window, oral semaglutide must be taken first thing on an empty stomach, swallowed whole with only a small amount of water, and you then wait about 30 minutes before eating, drinking anything else, or taking any other medicine.[4] Food, extra fluid or other tablets inside that window reduce how much semaglutide is absorbed.[4] Never crush, split or chew it. The instruction that counts is the one in the medicine's own patient information leaflet.
What the OASIS trials showed
The evidence behind the tablet comes from the OASIS programme, which tested once-daily oral semaglutide for obesity. The approval-supporting trial was OASIS 4, studying the 25mg tablet — the strength that reached the market — in adults with obesity, or overweight with a weight-related health problem, who did not have type 2 diabetes.[1]
Trials report weight loss two ways. The as-prescribed figure estimates the effect while people actually take the medicine; the real-world figure counts everyone, including those who stopped early. The first is higher. Both are legitimate, so we label which is which.
| Measure | Wegovy pill (25mg) | Placebo |
|---|---|---|
| Average weight loss — as prescribed | about −16.6%[1] | about −2.7%[1] |
| Average weight loss — real-world basis | around −13% to −14%[2] | about −2%[2] |
| Reached at least 20% weight loss (as prescribed) | about 1 in 3[1] | — |
For context, an earlier trial (OASIS 1) tested a higher 50mg dose and produced average weight loss of about 15.1% against 2.4% on placebo over 68 weeks.[3] That 50mg strength was not the one taken forward — the licensed tablet is 25mg — a reminder that a trial dose and an approved dose are not always the same. You can see these results alongside the other GLP-1 medications on our comparison page.
How the Wegovy pill differs from Rybelsus
This is the commonest point of confusion, because the UK already had an oral semaglutide tablet before the Wegovy pill: Rybelsus. They are the same molecule, made into a tablet by the same absorption-enhancer technology, and both must be taken on an empty stomach.[4] What differs is the dose and the licensed use.
| Rybelsus | Wegovy pill | |
|---|---|---|
| Active ingredient | oral semaglutide (a peptide) | oral semaglutide (a peptide) |
| Tablet strengths | 3mg, 7mg, 14mg[4] | up to 25mg[1] |
| Licensed for | type 2 diabetes[4] | weight management[1] |
| How it is taken | empty stomach, sip of water, then wait[4] | the same empty-stomach routine[4] |
In short: Rybelsus is the lower-dose, diabetes version of oral semaglutide; the Wegovy pill is the higher-dose version licensed for weight management. They are not interchangeable, and their dose ladders differ. For how the tablet stacks up against the other GLP-1 medications covered on this site, see our comparison page.
Side effects and safety
Because it is the same molecule as the injection, the Wegovy pill's side effects are the ones already known for semaglutide, and they are mostly gastrointestinal. For the injectable, the very common effects (at least 1 in 10 people) are nausea, diarrhoea, vomiting and constipation; they are usually mild to moderate, are dose-related, and tend to peak when the dose is increased before settling.[5] The exact per-symptom percentages for the 25mg tablet were not broken out in the sources we hold, so we do not copy the injection's numbers across as if they were the pill's.
Semaglutide also carries warnings that apply whatever the form: the risk of acute pancreatitis (stop and seek advice if severe, persistent stomach pain occurs), dehydration and, rarely, kidney problems from vomiting or diarrhoea, gallbladder problems such as gallstones, a higher risk of low blood sugar if combined with insulin or a sulfonylurea, and, in people with diabetes, monitoring for diabetic eye disease.[5] It should not be used in pregnancy; because it stays in the body for some time, women planning a pregnancy are reportedly advised to stop the tablet well beforehand.[5] A medicine's own approved product information is the definitive source for its full contraindications and warnings.
If you take any medicine and have a side effect, you can report it through the MHRA Yellow Card scheme[7], and you should also speak to your GP or pharmacist. Yellow Card reports help the regulator monitor the safety of medicines in real-world use.
Getting the Wegovy pill in the UK — the honest position
The Wegovy pill is a prescription-only medicine. The lawful route is a consultation with a qualified prescriber who decides whether treatment is appropriate and, if it is, dispensing from a pharmacy registered with the General Pharmaceutical Council (GPhC). We do not name or recommend providers, and we do not discuss price. Like the other GLP-1 drugs a UK reader might list, it is best thought of as one option a prescriber may discuss alongside diet and activity — not something to chase.
On the NHS, access to weight-loss GLP-1 medications is narrow and specialist-led, and a licence does not change that on its own; NHS funding would follow only after a separate NICE appraisal.[2][6] For how the injectable version is restricted on the NHS, see our Wegovy page. Note too that Ozempic — the same molecule licensed for type 2 diabetes — is not a licensed weight-loss product, and the MHRA says it has not assessed semaglutide used outside its licensed indication.[8]
Be very careful with any website advertising a cheap "Wegovy pill" or oral semaglutide without a prescription. Selling a prescription-only medicine to UK customers without a proper prescription is illegal, and whatever arrives may be a fake and could be dangerous. The government's FakeMeds campaign explains how to spot illegal online sellers. If you are considering a GLP-1 medication, start with a GP, pharmacist or other registered prescriber.
Frequently asked questions
Is the Wegovy pill available in the UK?
Yes. The MHRA licensed the Wegovy pill (oral semaglutide 25mg) on 11 June 2026 as the UK's first GLP-1 tablet for weight management.[2] It is prescription-only, so whether it is right for you is a decision for a qualified prescriber after a consultation. It is not routinely funded on the NHS at approval — that needs a separate NICE decision.[6]
How is the Wegovy pill different from Rybelsus?
How much weight did people lose on the Wegovy pill in trials?
Do you have to take the Wegovy pill on an empty stomach?
Yes. It is a peptide protected by an absorption enhancer, so it must be swallowed whole first thing on an empty stomach with a small amount of water, and you then wait about 30 minutes before eating, drinking or taking other medicines.[4] Food or extra fluid in that window reduces how much is absorbed.
Is the Wegovy pill the same as Foundayo?
No. Foundayo is orforglipron, a small-molecule (non-peptide) GLP-1 that can be taken at any time of day with or without food or water. The Wegovy pill is oral semaglutide, a peptide, which is why it needs the strict empty-stomach routine. See our Foundayo page for that medicine.
References
- Novo Nordisk. FDA approves Wegovy® in a pill — the first oral GLP-1 for weight loss (oral semaglutide 25 mg); OASIS 4 results. Company announcement, December 2025. novonordisk.com
- MHRA / GOV.UK. First GLP-1 tablet for weight loss approved in the UK (oral semaglutide, 11 June 2026). gov.uk
- Oral semaglutide 50 mg for adults with overweight or obesity (OASIS 1). The Lancet, 2023. thelancet.com
- US Food and Drug Administration. Rybelsus (oral semaglutide) prescribing information — 3/7/14 mg strengths, absorption enhancer and empty-stomach administration. accessdata.fda.gov
- emc. Wegovy (semaglutide) Summary of Product Characteristics — mechanism, side effects and warnings. medicines.org.uk
- NICE. Semaglutide for managing overweight and obesity (TA875). nice.org.uk
- MHRA. Yellow Card scheme — report a side effect. yellowcard.mhra.gov.uk
- MHRA / GOV.UK. Guidance for semaglutide prescribers and patients (Ozempic licensed for type 2 diabetes only). gov.uk